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Our study is aimed to characterize alteration in the immunohistochemical expres-
sion of p21 and p53 in normal tissue of the salivary gland surrounding carcinoma
arising in pleomorphic adenoma, and the tumor cells of carcinoma arising in pleo-
morphic adenoma as well as to identify whether the induction of expression p21 is
dependent on or independent of p53 in carcinoma arising in pleomorphic adenoma.
A selected series of 27 cases of carcinoma ex pleomorphic adenoma (undifferentiat-
ed and adenocarcinoma types) was examined.
The results showed that p21 and p53 expression was negative in the most compo-
nents of normal tissue of the salivary gland surrounding carcinoma arising in pleo-
morphic adenoma. p21 was strongly expressed in carcinoma cells in 9 (33.3%) cas-
es out of 27. p53 was strongly expressed in carcinoma cells in 10 (37%) cases out
of 27. Also a co-expression of p21 and p53 showed negative nuclear staining in
9 cases, while 8 cases expressed positive staining. p21 expressed negative nuclear stain-
ing in 4 cases but p53 expressed positive staining in the same cases. p21 expressed
positive nuclear staining in 6 cases but p53 expressed negative nuclear staining in
the same cases.
Our data suggest that inactivation of p53 and p21 may play an important role in the evo-
lution of carcinoma ex pleomorphic adenoma. Also p21 behaves as dependent on or
independent of p53 in carcinoma arising in pleomorphic adenoma.
Key words: p21 expression, p53 expression, pleomorphic salivary adenoma, car-
cinoma ex pleomorphic adenoma.
Introduction
Carcinoma ex pleomorphic adenoma (CPA) is con-
sidered to be a malignant transformation product of pre-
existing pleomorphic adenoma [1]. Carcinoma ex
pleomorphic adenoma is the most common malignant
mixed tumor and has been estimated to account for 10%
of all salivary gland malignancies [2]. The current stud-
ies of the molecular biology of cancers have demon-
strated that the loss of function of the tumor suppressor
gene such as p53 and p21 may lead to the development
of many different cancer types [3-6]. Mutation
of the p53 tumor suppressor gene, located on the short
arm of chromosome 17, is among the most common-
ly detected genetic abnormalities in human neoplasia.
p21 is a cell cycle regulatory protein encoded by the p21
WAF 1 gene which is located on chromosome 6p21.2
[7, 8]. It is believed that the inhibitory effects on cell
division by p21 are related to cancerous change of nor-
mal cells, regulation, cell differentiation and induction
of apoptosis involving p53 and Rb [9]. The aim of this
study was to characterize the alterations and aberrations
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in the expression of p21 and p53 in carcinoma ex pleo-
morphic adenoma and also to evaluate whether p21 ex-
pression in carcinoma ex pleomorphic adenoma was
functionally related or unrelated to p53 expression.
Materials and methods
Case selection
A selected series of 27 cases of carcinoma ex pleo-
morphic adenoma was retrieved from the files
of the Oral Pathology Department in Alfarabi Den-
tal School (Table I). Normal tissue of the salivary gland
surrounding the tumour was used as a control in 27
cases of carcinoma arising in pleomorphic adenoma.
The immunohistochemical expressions of antibodies
against p21 and p53 were examined in the selected cas-
es. The criteria for defining carcinoma ex pleomorphic
adenoma proposed by Nagao et al. [10] were used to
select and reclassify our cases of carcinoma ex pleo-
morphic adenoma. According to the World Health Or-
ganization histological classification published in
2005, malignant changes in the pleomorphic adeno-
ma include three different types: CPA, carcinosarco-
ma, and metastasizing pleomorphic adenoma. The in-
clusion criteria for carcinoma ex pleomorphic adenoma
comprised major gland primary lesions (parotid or sub-
mandibular) and the macroscopic features that suggest
malignant transformation in pleomorphic adenoma in-
cluding poorly defined and/or infiltrative tumor mar-
gins, the presence of foci of hemorrhage, and necrosis.
Also the co-existent benign and malignant elements
are considered as well. Benign elements can be pleo-
morphic adenoma within the tumor mass, biopsy proven
history of previous pleomorphic adenoma indicating that
it was in the same location as the subsequent carcinoma.
Malignant elements can be undifferentiated carcino-
ma, adenocarcinoma, and multiple patterns of differ-
entiation including undifferentiated or adenocarcino-
Table I. Clinical data of 27 carcinoma ex pleomorphic adenomas cases (CPA)
CPA CASES AGE (YEARS) GENDER GLAND HISTOLOGICAL SUBTYPE METASTASIS TO LYMPH NODES*
1 77 F parotid adenocarcinoma yes
2 28 M parotid adenocarcinoma no
3 78 M submandibular undifferentiated yes
4 45 M parotid undifferentiated yes
5 76 F parotid undifferentiated no
6 82 F parotid undifferentiated no
7 71 M parotid adenocarcinoma no
8 67 M submandibular undifferentiated yes
9 63 M submandibular undifferentiated yes
10 55 M submandibular undifferentiated yes
11 73 M parotid undifferentiated yes
12 71 M parotid undifferentiated no
13 64 M parotid undifferentiated yes
14 60 F parotid undifferentiated yes
15 49 F submandibular undifferentiated no
16 39 F parotid undifferentiated yes
17 56 M parotid undifferentiated no
18 45 F parotid undifferentiated yes
19 57 M parotid undifferentiated yes
20 66 F parotid undifferentiated no
21 86 F submandibular undifferentiated yes
22 17 F parotid undifferentiated no
23 78 M submandibular undifferentiated yes
24 26 M parotid undifferentiated no
25 31 F parotid undifferentiated no
26 71 M parotid undifferentiated no
27 71 M parotid undifferentiated no
F – female, M – male
*metastasis to lymph nodes at the time of tumor resection
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ma patterns. Exclusion criteria for carcinoma ex pleo-
morphic adenoma include other well-recognized sali-
vary carcinomas and those of uncertain type included
in the current WHO histological classification of tu-
mors [11]. Microscopic slides stained with hematoxylin
and eosin were reviewed by two pathologists to con-
firm the histopathological diagnosis and to reclassify
the studied cases. The carcinoma cases were classified
according to the above-mentioned criteria as undif-
ferentiated carcinoma or adenocarcinoma. The ethical
approval was provided by the research ethics committee
(Ref. 05/109).
Immunohistochemistry
Paraffin-embedded tumor samples stored in pathol-
ogy laboratory files were used in this study. A series of 4-
µm-sections was consecutively cut from all 27 specimens.
The sections were deparaffinized in xylene and rehy-
drated through graded alcohols. Sections were processed
using the streptavidin-biotin-peroxidase method.
Briefly, the endogenous peroxidase was blocked by 3%
hydrogen peroxidase for 5 min followed by TBS (tris-
buffered saline) wash. Nonspecific immunoreactivity was
blocked by incubation with normal goat serum for
20 minutes. A purified mouse anti-human monoclon-
al antibody p21 (Pharmingen, San Diego) was diluted
to 10 µl/ml in 20 µl/ml tris-buffered saline containing
0.1% bovine serum albumin for one hour and fifteen
minutes at room temperature. A primary antibody P53
monoclonal mouse antihuman (clone, D-O7: Dako) was
diluted to 1 : 25 (40 µl/ml) in tris-buffered saline (TBS)
containing 0.1% bovine serum albumin for 2 hours at
room temperature. All sections were washed by TBS for
5 minutes. Sections were incubated with the biotiny-
lated secondary antibody reagent for 30 minutes fol-
lowed by TBS wash for 5 minutes. Slides were incubated
with streptavidin and horseradish peroxidase for 30 min-
utes followed by TBS (tris-buffered saline) wash for
5 minutes and incubated with a prepared chromogenic
substrate solution (Diaminobenzidine) for 15 minutes.
Sections were counterstained with 0.25% methyl
green in distilled water for 5 minutes. Sections were de-
hydrated and mounted in Depax. Squamous cell car-
cinoma was used as a positive control. A negative con-
trol was used only with substitution of the primary
antibody with TBS (Figs. 1A, 2A). The percentage
of p35 and p21 positive nuclei was semi-quantitative-
ly assessed by two independent observers and scored as
negative (0) no expression of nuclear protein, (1) weak
staining: 0-25% of the total cells show positive stain-
ing in the nucleus, (2) moderate staining: > 25-75%
of the total cells in the test area show positive nuclear
staining, and (3) strong staining: > 75-100% of cells
show positive nuclear staining.
Fig. 1. Nuclear staining of p21 in normal tissue surrounding carcinoma arising in pleomorphic adenoma (original
magnification 40×). A – p21 negative control; B – negative nuclear staining of p21 in ductal and acinar cells in
parotid gland; C – strong nuclear staining of p21 in CPA; D – moderate nuclear staining of p21 in CPA
A B
C D
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Statistical analysis
Cells of carcinomatous component of the CPA were
always scored. The statistical analysis included the use
of descriptive statistics; frequencies proportion. Also,
statistical analyses, including Mann-Whitney and
Wilcoxon’s nonparametric tests (ordinal data), were per-
formed on the data. All statistical tests were two-sided
and p-values less than 0.05 were considered to be sta-
tistically significant.
Results
p21 expression in the control group
(normal tissue) surrounding carcinoma arising
in pleomorphic adenoma
Of the 27 cases, p21 expression of the non-tumor
duct cells was negative in 25 (92.59%) and weak in
2 cases (7.40%) cases with weak staining. p21 (nuclear
staining of the acinar cells) showed negative staining
in 27 (100%) cases out of 27 (Fig. 1B). p21 (nuclear
staining in stroma) was negative in 27 (100%) cases
out of 27.
p53 expression in the control group
(normal tissue) surrounding carcinoma arising
in pleomorphic adenoma
Three components (duct, acinar cells, and stroma)
were examined in the normal tissue adjacent to carci-
noma arising in pleomorphic adenoma (Fig. 2B). We
evaluated the percentage of p53-positive cells in each
case, with the use of the frequency test. Nuclear stain-
ing of non-tumor duct cells indicated that p53 showed
weak positive staining in 15 (55.55%) cases out
of 27, and 12 (44.44%) cases had no expression, where-
as the expression of p53 cytoplasmic staining was pres-
ent in non-tumor duct cells as follows: 3 (11.11%) cas-
es out of 27 with low staining, and 24 (88.88%) with
negative staining.
p53 expression in carcinoma arising
in pleomorphic adenoma
p53 was strongly expressed in carcinoma cells in 10
(37%) cases out of 27. Moderate staining was seen in
2 (7.4%) cases and 15 (55.6%) cases expressed nega-
tive staining (Fig. 2C, D). Wilcoxon test showed a sig-
Fig. 2. Nuclear staining of p53 in normal tissue surrounding carcinoma arising in pleomorphic adenoma (original
magnification 40×). A – p53 negative control; B – negative nuclear staining of p53 in ductal and acinar cells in parotid
gland; C – moderate nuclear staining of p53 in carcinoma arising in pleomorphic adenoma; D – strong staining of p53
in carcinoma arising in pleomorphic adenoma
A B
C D
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nificant difference (p value < 0.001) between p 53 ex-
pression in the nuclei of duct cells in normal tissue sur-
rounding carcinoma arising in pleomorphic adenoma
(control group) and the tumor area.
p21 expression in carcinoma arising
in pleomorphic adenoma
p21 was strongly expressed in carcinoma cells in
9 (33.3%) cases out of 27 (Fig. 1C). 5 (18.5%) cases
showed moderate staining (Fig. 1D), 5 (18.5%) cases
expressed low staining, and 8 cases (29.6%) – nega-
tive staining. Wilcoxon test showed a significant dif-
ference (p value < 0.001) between p21 expression in
the nuclei of duct cells in normal tissue surrounding
carcinoma arising in pleomorphic adenoma (control
group) and the tumor area.
Comparison of p21 and p53 in carcinoma
arising in pleomorphic adenoma
It was considered that p21 and p53 strong and mod-
erate nuclear staining was classified as positive, and an
indicator for altered p21 and p53 carcinoma arising in
PSA. Low and negative nuclear staining was classified
as negative and indicated the wild type (non altered
p21, and non altered p53). In carcinoma arising in pleo-
morphic adenoma, p21 staining was positive in 14
(51.8%) cases out of 27, and p53 staining was positive
in 12 (44.4 %) cases out of 27. Mann-Whitney test
showed no significant difference (p value > 0.001) be-
tween expression of p53 and p21 of the nuclear posi-
tive staining in 27 cases of carcinoma arising in pleo-
morphic adenoma.
Co-expression of p21 and p53 in carcinoma
arising in pleomorphic adenoma
The nuclear staining in the carcinoma cases was re-
classified to study the relation between p21 and p53.
Low and negative staining was considered negative and
moderate, while strong nuclear staining was considered
positive.
p21 and p53 showed negative nuclear staining in
9 cases, while 8 cases expressed positive staining. p21
expressed negative nuclear staining in 4 cases but p53
expressed positive staining in the same cases. p21 ex-
pressed positive nuclear staining in 6 cases but p53 ex-
pressed negative nuclear staining in the same cases
(Table II). This means p21 behaves as dependent on
or independent of p53. p21 expression in carcinoma
arising in pleomorphic adenoma is shown in Fig. 7.
Discussion
No study has been published regarding p21 ex-
pression dependent on or independent of p53 in sali-
vary glands and particularly in carcinoma arising in pleo-
morphic adenoma.
p21 WAF 1 is synthesized in order to arrest the cell cy-
cle (G1 or S) through both dependent and independ-
ent p53 pathways [9]. It has been reported that p21 ex-
pression in oral cancer was functionally unrelated to p53
expression (Yook and Kim [12]). El Deiry et al. [7] found
that p21 was induced in p53 mediated G1 arrest and
apoptosis. Michalides et al. [5] demonstrated a pathway
for p53 independent induction of p21. Jung et al. [13]
studied glioblastoma tumors (high grade). Both p53 de-
pendent and p53 independent mechanisms of p21 ac-
tivation account for p21 expression in these tumors.
Erber et al. [14] found that p21 accumulation was
independent of the genetic status of p53 in head and
neck tumors.
Rey et al. [15] studied p21 expression, which was
independent of p53 overexpression in breast cancer.
Only 20 carcinomas showed p53 overexpression but
Table II. p21 and p53 co-expression of the nuclear stain-
ing in carcinoma cases
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p21 was negative in these cases, thus providing evidence
for the existence of p53 independent mechanisms for
p21 regulation.
Yook and Kim [12] reported that the expression
of p21 was independent of p53 in oral squamous cell car-
cinoma. p21 was expressed in 15 out of 20 cases. Of
the 13 tumors, which were the wild type for p53, 9 show-
ed positive staining for p21, 6 out of the 7 cases with
demonstrated p53 mutations stained similarly for p21.
The results of carcinoma arising in pleomorphic ade-
noma showed that 12 cases (44.4%) expressed mod-
erate or strong staining of p53. This is comparable to
the frequencies of 67% [16] and 75% [3] reported in
the literature. Also p21 staining was positive in 14
(51.8%) cases out of 27. All of these results are con-
sistent with literature.
Li et al. [17] studied the numeric aberrations
of chromosome 17 and p53 gene deletion carcinomas
arising in pleomorphic adenoma. Polysomy was observed
in 19.6% of carcinoma cells, and monosomy of chro-
mosome 17 was shown in 30.8% of CPA cells (carci-
noma in pleomorphic adenoma). Immunohistochem-
ical staining showed p53 was expressed in 6 out of
9 CPA cases (66.7%). Yamamoto et al. [18] found
a high rate of mutations (loss of heterozygosity) as
the p53 gene was detected in cases of carcinoma aris-
ing in pleomorphic adenoma (58%). Nordkvist et al. [19]
studied 24 cases of carcinoma ex pleomorphic adeno-
ma. 17 cases showed p53 expression. 9 cases with pos-
itive p53 staining had 1-10% of positive cells,
5 cases showed positive p53 staining in 11-50%
of the cells, and 3 cases showed very strong staining
of p53 in 51-100% of the cells. p21 belongs to a class
of tumor suppressors including p16 and p27, which con-
trol progression through the cell cycle by inhibiting
the activity of cyclin-cdk complexes. De Lima
et al. [20] reported that no expression of p21 was found
in adenoid cystic carcinomas. Tarakji and Nassani [21]
reported that p21 was strongly expressed in carcinoma
arising in pleomorphic adenoma in 9 (33.3%) cases out
of 27. In view of the central role of p21 in inducing
growth arrest, terminal differentiation, or apoptosis, al-
terations in p21 expression may reflect a vital role in
the pathogenesis of carcinoma arising in pleomorphic
adenoma in both p53 dependent and independent cas-
es. The published literature on tumor markers in CPA
is limited due to the fact that these tumors are rare.
The present results are consistent with these studies.
Conclusions
These results suggest that induction of p21 occurs
by both p53 dependent and independent mechanisms
during development of carcinoma arising in pleomorphic
adenoma.
The authors declare no conflict of interest.
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